CA1200483A - Device and method for determining the presence of antigens - Google Patents

Device and method for determining the presence of antigens

Info

Publication number
CA1200483A
CA1200483A CA000411489A CA411489A CA1200483A CA 1200483 A CA1200483 A CA 1200483A CA 000411489 A CA000411489 A CA 000411489A CA 411489 A CA411489 A CA 411489A CA 1200483 A CA1200483 A CA 1200483A
Authority
CA
Canada
Prior art keywords
zone
antigens
antibodies
enzyme
linked
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
CA000411489A
Other languages
French (fr)
Inventor
Lance A. Liotta
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Application granted granted Critical
Publication of CA1200483A publication Critical patent/CA1200483A/en
Expired legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/558—Immunoassay; Biospecific binding assay; Materials therefor using diffusion or migration of antigen or antibody
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54366—Apparatus specially adapted for solid-phase testing
    • G01N33/54386—Analytical elements
    • G01N33/54387—Immunochromatographic test strips
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/52—Use of compounds or compositions for colorimetric, spectrophotometric or fluorometric investigation, e.g. use of reagent paper and including single- and multilayer analytical elements
    • G01N33/525—Multi-layer analytical elements
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54366—Apparatus specially adapted for solid-phase testing
    • G01N33/54386—Analytical elements
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/805—Test papers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/97—Test strip or test slide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/807—Apparatus included in process claim, e.g. physical support structures
    • Y10S436/81—Tube, bottle, or dipstick
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/815—Test for named compound or class of compounds
    • Y10S436/817—Steroids or hormones
    • Y10S436/818—Human chorionic gonadotropin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/82—Hepatitis associated antigens and antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

DEVICE AND METHOD FOR DETERMINING
THE PRESENCE OF ANTIGENS

Abstract Of The Invention A device is provided for determining the presence of antigens which comprises a first zone containing antigens and enzyme-linked antibodies which are capable of immunologically reacting with said antigens, said antibodies being positioned in said first zone such that they will be removed from said first zone when reacted with antigens passing through said first zone but not removed from said first zone in the absence of such antigens, and a second zone containing material capable of reacting with said enzyme-linked antibodies to produce a color forming reaction which indicates the presence of said antibodies.

Description

~l2 ~ 3 Background o~ the Invention The present invention relates to a device and method for determining the presence of antigens in biological fluidso Immunologic diagnostic tests are widely used for the detection of body fluid antigens, hormones, infectious agents, and serum antibodies. Immunoassays generally fall into the follo~.~ing two categories. First, antibod~-antigen precipiLation tests, such as radial immunodiffusion, hemagglutination, and coa~ed latex particle agglutination. Second, labeled-reagent tests, such as radioimmunoassay, and enzyme-linked immunoassay, The precipitation type tests have the advantage of being performed manually and are commercially used in disposable kits which are read visually and do not require an instrumentO The reading from a precipitation type immunoassay is usually expressed as the presence or absence of an agglutination reac-tion at each of a series of known dilutions of the test sample or competing antigen, The disadvantages of the precipitation type tests is that they are much less sensitive than the labeled reagent assays, require time consuming incubation steps, and are susceptible to subjective error in visual identification of a precipitation reaction.
Labeled reagent immunoassays are quantitative and highly sensitive but, nevertheless, have certain disadvantages, Radio-immunoassays employ radioactive tracers and, therefore, require a gamma radiation detection instrument, The radioactive tracers have a short shelf life, pose a hea]th hazard to the technician and have been subject to restrictive legislationO Enzyme-linked immunoabsorbant assays (ELISA) use reagents labeled with an enzyme~ The enz~Jme is detected by its reaction with a substrate ~o yield a produc~ that can be easily measured (for example by : formation of a color). The ELISA does not require radioactive materials and uses reagents with a long shelf life~ ~

~ 3 The ELISA assay beings with the bindi.ng of a reference reagent to a solid phase support, such as the bottom of a plas-tic well~ Test fluid, mixed with enzvme-labeled reagent, is reac~ed with the bound reference reagent. Through a number of dilution, incubation and washing steps (as many as fourteen), bound and free reagents are separated a and a color forming reac-tion is initiated. The intensity of the color formed at dif-ferent serial clilutions provides the quantitative measureO The standard ELISA takes bet~een four and twelve hours ~o perform.
Consequently, the major disadvantage of the ELISA i5 the large number of dilution, incubation, and washing steps, which are time consuming ancl subject to error.
The device of the present invention is used to overcome many of the difficulties associated with the above-discussed type of assay~ Speci~ically, the use thereof results in an improved ELISA which requires no dilution, no washing steps, and one short incubation period. The assay i5 in the form of a dry, layered test strip which orms a color reaction when exposed directly to the test fluid. The strip automatically performs the dllu-tion steps required Cor quantitation and separates the bound antibody from the free antibody. The color reaction can be read visually, or with an instrument, such as a spectrophotometer.
In additlon, the device o~ the present invention can be iEabri-; cated in strip form and employed as a dipskick for rapidLy de-tecting an antigen) such as a drug or hormone in urineO An example of a specific application would be the rapid detectlon of a drug overdose in the Emergency P~oom, or as a home pregnancy test, Summarv of the Invention In one aspect, the present inventlon concerns a device for determining the presence of ant.igens which comprises a first zone containing antlgens and enzyme-linked antiboclies wh:ich are capable of 1.mmunologically reactiny with said antigens, said antibodies being posi.-tioned in said first zone such that they will be removed from said first zone when reacted with antigens passing through said first zone but not removed from said first zone in the absence of such antigens, and a second zone contain-ing material capable of reacting with said enzyme-linked anti-bodies to produce a color forming reaction which indica-tes -the presence of said antibodies.
In another aspect, the instant invention is directed to a unique method for determining the presence of antigens in a biological fluid which comprises bringing said fluid in-to con-tact with a device or matrix having a first zone containing antigens and enzyme-linked antibodies which are capable of im-munologically reacting with said antigens, said antibodies bei:ng positioned in said first zone such that they will be removed from said first zone when reacted with an-tigens passing through said first zone but not removed from said :Eirst zone in the absence of such anti.gens, and a second zone containing material capable of reacting with said enzyme-lin]~ed antibodies -to pro-duce a color forming reaction which indicates the presence of said anti.bodies; allowing said fluid to permeate said device or matrix; and observing the presence or absence of any color cha:nge in said second zone to thereby determine the presence or absence of the tested for antigen in said fluid.
; 25 According to a further aspect of the presnet invention there is provided a device for determining the presence of anti-bodies which comprises a first zone containing enzyme-linked antigens and antibodies which are capable of immunologically reacting with said antigens, said antigens being positioned in said first zone such that they will be removed from said firs-t zone when reacted with antibodies passing through said first zone but not removed from said first zone in the absence of such antibodies; and a second zone containing material capable , ~ of reacting with said enzyme-linked antigens to produce a color forming reaction which indicates the presence of said antigens.
~ ccording to a sti.ll further aspect of the present invention there is provided a method for determining the presence oE antibodies in a biological fluid which comprises bringing a fluid which is to be tested for the presence of antibodies into contact with a device having a -Eirst zone con-taining enzyme-l.inked antigens and antibodies which are capable of immunologically reacting with said antiyens, said antigens being positioned in said first zone such that they will be removed from said first zone when reacted with antibodies pass-ing through said first zone but not removed from said first zone in the absence of such antibodies, and a second zone containing ma-terial capable of reacting with said enzyme-linked antigens to produce a color forming reaction which indicates the presence of said an~igens; allowing said fluid to permeate said device;
and observinc~ the presence or absence of any color change in said second zone to thereby determine the presence or absence of the tested for antibodies in said fluid.

- 3a -~ 3 a porous material and has bound thereto antigens 260 La~Jer 16, likewise, is fabricated from a porous material and contains a bound color-forming reagent 17, iOeO, a ma~erial which reacts with an enzyme to produce a colorO
Figure 2 is a diagrammatical illustration showing the method of the invention using the device of Figure 1. Specifi-cally, a fluid, generally identified by the numeral 28, is applied to the sur~ace 30 of layer 12. As the fluid diFuses through the matrix, free antigen 32 contacts and combines with enzyme-linked antibodies 24 After a short incubation per~od, the enzyme-linked antibodies w~t1.t saturated recogn~tion sltes freely diffuse throu~h first zone 18 and into the second zone 20 (or la~Jer 16) where the enzyme reacts ~with the color forTning reagent to produce a distinctive color which indicates the pre-sence o antigen in the applied fluido Figure 3 is a diagrammatical illustra~ion showing the method of the invention using the device o Figure l and showing what happens when the test ~luid is devoid of an~igenO ~peci-fically, A fluid, generally designated 34, is applied to the sur-~0 face 30 of layer 12. As the luid difluses through layer 12 o~
the matrix, enzyme-linked antibodies 24 are solubilized and moved into layer 14 where the~J engage and become attached ~o bound an-tigens 26, Accordingly, no enzyme-linked antibodies reac'n the color forming reagent 17 in layer 16 (second zone 20) and no color change is observedO ~hls, of course, indicates that no antigens were present in the fluid 34.
~igure ~ sho~s an alte~native embodiment of the invention wherein the device or matrix 11 is formed in two distinct layers 36 and 3~ Tn thîs case, layer 36 is the first zone 40 having therein bound reference antigen 44 ~hich i5 combined with enæ-~me-linked antibody 460 La-yer 38 is the second zone 42 and con~ains color forming reagent 170 ~ 3 As shown in Figure 5, w'nen the test fluid 48 contains suf.ficient free antigen 50 to compete with the bound antigen 44, the enzyme-linked antibody will be displaced and will diffuse do~n lnto 7one ~2 to produce a color reaction 520 ConverselY, as sho~n in Figure 6, when the test fluid 54 is devoid of antigen, no competition w~ll take ~lace, and con-seauently no enzyme-lin~ed antibody will diffuse into second zone 42 and no color will be produced~
~escri~tion of the Practice of the Tnventlon The present invention is based on the ~rinciple of com-pet tion between bolmd and free anti~ens for a fixed number of recognition sites on an enzYme-labeled antibody, It is an improved method for performing the F,LISA type test. The rea~9ents of the assay are impregnated into a multl-z~ned test stri~0 lhe liquid sample to be tested is allowed to passively diffuse into the test strip. ~ound and free antigens are automatically separated during the diffusion. This separation is accomplished by having the solid phase reference antigen immobiliæed i.n a first zone which is separate from a second zone containing the enzyme substrate. Soluble enzyme-linked antibody, which has recognition sites, is allowed to mix with the test sample and diffuse through the layers. The soluble antigens in the test sample compe~e with the immobilized reference antigen or com-bining with the enz~rme-linked antibody. Therefore, the amount of enzyme-linked antibod~,r which ultimately reaches the second zone containing the substrate, depends on the concentration of the antigen being tested in the sampleO The substrate in the test strip reacts with the enzyme to produce a color reactionO
In order to provide quantitation the test s~rip is con-structed with mulkiple~ separate regions9 each containin(g a different amount of immobilized reference antigen, ~he posi~ior of the color change on the test strip is, therefore, dep~ndent on the concentrakion of the antigen in the test sample, As hereinbefore noted, the device of the present inven-tion includes a first zone which contains bound antigen and speciic enzyTne~linked antibodv and a second zone which contains a color forming reagent or substra~e. The enzyme-linked anti-bodies are positioned in the Eirst zone in such a manner that they are capable of beiTlg removed from thP first zone when reacted with unbound antigen enterin~ or passing therethrough but not removed from the first zone in the absence of such anti-gens.
In the preferred practice of the invention t~e immunoas-say device is a sandwich of three, porous matrix layers (see Figure 1), The first porous layer is impregnated with a specific antibody linked with an enzyme. The second porous layer contains immobiliæed (bo~md) reference antigen. The anti~en is of the type specifically recognized b~ the antibody in the first porous laver. The third layer contains a color forming substrate which reacts with the enzyme linked to the antibody. The operation oE
the device is as ~ollows (see Figures 2 and 3).
The fluid sam~le, containing the antigen to be tested, is
2~ placed in contact with the first layer. The free antigen in the test sample diffuses into the second layer and then iTltO the third layer. The free antigen in the sample competes with the i~mo~ilized bound reference antigen in the second laver for com-bining with the enzyme-linl;ed antibodvO If the enzyme-linked antibody combines with free antigen, it will freely diffuse into the third layer and produce a color reaction. If the fluid sample contains no antigen, all the enzyme-linked antibody will have free binding sites and will combine with the immobillzed antigen in the second layer. F.nzvme-linked antibody which co~-bines with the immobilized antigen in the second layer will not diffuse into the third l~yer~ and no color reaction will be produced. The difference in the amount of substrate degraded (and intensity of color produced) is proportional to the amount ~ ~ ~U~ 3 of antigen in the test sample. For a given amount of enzyme-l~beled antibod~J in the first layer, the sensitivity of the device is determined by the amount of reference antlgen present in the second layer~ Typically, a test device would con~ain a series of sandwich composites, each with a different amount of reference antigenO The series of reference antigen concentra-tions would have been previously determined to span a range of sensitivity, appropriate for the test solutiorl being measured.
It should be emphasized that in the ELISA test strip a positive color reaction indicates the presence of the antigen being testedO
The materials used to fabricate the device of the instant invention are well known in the art. However, in practice it has been ound to be desirable to form the æones or layer of the pre-ferred device from interwoven fibers such as nitrocellulose or dia~obenæyloxymethyl (DBM) paper. Nitrocellulose paper directly binds proteins and has been shown to be useful for immobilizing antigens. DBM matrix binds DNA, R~A, and proteins by means of covalent linkages to the diazonium group. ~dditionally, a oor-ous gel such as ~olyacrylamide J agarose, or collagen can be utilized. The antigen can be trapped within the pores of the gelJ or it can be cross-linked to the gel via amino groups of the ligand and carboxylic groups on the matrix Also, particles or beads containing the bound ligand trapp~d within a cellulose or plastic flber matrix can be employed, A satisfactory example i5 polyacrylamide beads, 5-10 microns in diameter, with antigen bound to the surface via a peptide bond. The beads are trapped within a cellulose filter matrix of pore size 1-2 microns~
Suitable substrates or color-forming reagents are well known in the art. In this regard, a number of different types of purified enzymes are commonly labeled reagent for use in im-munoassays such as ELISA. These include horseradish peroxidase, alkaline phosphatase, and beta-galactosidase. However, the present invention is not limited to the use of these enzymes to label the antibody or antigen. The enzyme used to label the an-tibody can produce a color in the second zone of the test device by acting directly or indirectly with the color forming agent. For example, substrates well known in the art such as diaminobenzidine or p-nitrophenylphosphate react with horse-radish peroixdase in the presence of hydrogen peroxide to form a brown color to black color. In one form of the present invention hydrogen peroxide is added exogenously during the use of the device. Alternatively, the lyophilized color forming zone can contain bound glucose oxidase and the first zone can contain glucose. Upon use of the device, the glucose in the first zone diffuses into the second zone and generates hydrogen peroxide by reacting with glucose oxidase.
The enzyme linked to the antibody can produce a color in the second zone by an indirect means such as effecting the permeability of the zone. An example of this method found suitable for the present invention is the use of highly purified collagenase as the enzyme linked to the antibody. This enzyme degrades collagen into small peptides. To detect the collogenase label two reagents which combine to form a color are separated by a collogen matrix barrier. The presence of the collogenase labeled antibody is detected because the collogenase degrades the collogen barrier and allows the separated reagents to intermix arld form a color. A suitable collogenase is that obtained from clostridium histolyticum purified by means well known in the art. A suitable collogen matrix is that formed by bovine type I collogen in -triple helical (native) or denatured (gelatin) form.

The following are specific examples which fur-ther illustrate the practice of the instant invention.

TEST: Three Layer Ernbodlment Of The Invention For Pregnancy Detection Materials Utilized:
a) antigen: human chorionic gonadotrophin (hCG) b) antibody: rabbit antisera to human hCG
c) enzyme linked to antibody: horseradish peroxidase d) color forming enzyme substrate: diamino benzidine e) matrix material forming porous layers: nitro-cellulose.
Procedure:
Step 1. Preparation of layer containing color forming reagent: Nitrocellulose matrix sheets 0.2 mm thick were cut into strips 2 cm wide and 10 cm in length. The sheets were soaked for thirty minutes in a solution of 0.1 mg/ml diaminoben-zidene in distilled water. The sheets were then frozen by coveriny them with dry ice pellets. The frozen sheets were lyophilized in a conventional lyophilizer.
Step 2. Preparation of antigen--con-taining layer: anti-gen was solubilized into phosphate buffered saline at a concen-tration oE 5.0 I.U./ml, and made up as in a series of dilutions:
1:1, 1:2, 1:4, 1:8, 1:16, 1:32, :L:64 and 1:100.
Eight groups of nitrocellulose sheets were each soaked in a diEferent dilution of the antigen solution for thirty minutes at 4C. All sheets were then soaked in a solution of 1%
bovine serum albumin in phosphate buffered saline for two hours at 4C to saturate all the free protein binding sites on the ~; nitrocellulose. (Tobin et al Proc. Natl. Acad. of Sci. 76 4350-4354, 1979.) The sheets were then lyophilized as above.
Step 3. Preparation of enzyme-linked antibody con-taining layer: Peroxidase enzyme was conjugated to the antibody by the standard periodate _ g _ ~ 3 method of ~ilson and Nakane (1978 in l~Jo Knapp et al (ed.) In~uno-fluorescence and Related Techniques, Elsevier CoO, Amsterdam, pO 215 225). After purifying the conjugate by standard methods it was made up in PBS at a concentration of 1 mg/ml, The concen-tration of enzyme-linked an~ibody to be impregnated in the layer was determined by diluting the enzyme-linked antibody soLu-tion until a 20 microliter droplet applied to the surface of ~he Vb.`~
nitrocellulose sheet containing ~EE~e~i~ antigen at a dilu-tion of 1:32 showed complete binding of all the antibody to the immunobilized antigen (preparation of a standard dilution curve), This concentration of enzyme linked antibody was soaked into strips of cellulose blotter paper material and lyophilized as described for Step 1 above.
Step 4. Preparation of three-layer sandwich: 1 cm squares of each lyophilized layer were cut from the stripsO The solid support was a strip of polycarbona~e transparent p:Lastic 10 cm x 1 cm x 0Ol mm thicko Eight squares of nitrocellulose containing the color forming substrate were cemented to the plas-tic support with latex base cementO On top of these squares the ; 20 antigen containing sheets were cemented using latex cement at the perimeter. The eight different antigen concentrations wereused. Fi.nally, on top of ~he antigen layers, the enzyme--linked antibody layers were glued.
Step 5O To perform the assay7 fifty microliters of -the test solution was applied to the surface of the top layerO The test solution consisted of standard antigen in phosphate buffered saline Ph 7.4 with 0O1% hydrogen peroxide~ The sensitivity of the assay was 0O3 IU of hCG which exhibîted a color react:ion at the 1:~2 dilution of immunobilized antigenO
~esults The ELISA test strip fabricated as described above was compared for sensitivity to a standard hemagglutination reactionO

-10~

The test sample was pooled human urine from six patients who were previously determined to be pregnant~
DILUTIO~ OF ESTI~ATED ELISA CONVENTIONAL
URINE SAMPLE hC~ DETECTED STRIP HEMAGGLUTINATION
S 1:1 2.5 IU (~) (+) 1 2 lo 2 IU (+) (+) 1:4 OvS IU (+3 (-) 1:8 003 IU (~
1 16 Oo O1 IU (-) (-) The sensitivity of the ELISA strip is greater than the conven-tional hemagglutination reaction.
E ~MPLE 2 TEST: (a) To determine the time of color formation for various concentrations o enzyme-linked antibody lmpregnated lnto the first layer of the three layer embodimen~.
(b) To determine the feasibility of detecting human hepa-titis B antigen (HBA) o Procedure:
The test strip was constructed by methods identical to Example lo The first layer contained lyophilized cellulose matrix impregnated with the following dllutions of peroxidase conjugated antl-HBA: 1/2, 1/5, 1/50, 1/225, 1/625, l/31250 In experiment a) the second layer contained no antigenO In experi-ment b) the second layer contained bound HBA at a concentration of 500 nanograms per square cmO The third layer contained DAB
substrate prepared as in Example 1 for detec~ion of hCG.
R~ST~5 Experiment a) The test sample consisted of normal h~man serum diluted 1/10 in phosphate buffered saline containing 0. l~/o hydrogen peroxideO

COT.,OR REACTION
Dilution time: 10 sec 30 sec 1 mi.n 1/2 d~ep BN-BLK same same 1/5 deep BN-BLK same same 1/50 BN-BLK same same 1/225 BN dark BN same 1/625 light BN BN dark BN
1/3125 no color very light ligh~ BN
BN
KEY: BNGbrown, BLK~black Conclusion: The o?timal concentration of enzyme-linked antibody -is 1/625 when the second layer contains 500 nanograms of HBA
per square cm. The feasibility of detecting HBA is demonstrated by the presence of competi~ion of the free antigen for the bound reference antigen at l/6250 Experiment (b?.l Determination of optimum maximal concentration of enzyme linked antibody in the first layer which is co~pletely bound to the reference antigen in the second layer when the test sample is devoid o antigen.
Dilution o Rnzyme Conjugated Color Reaction ~t One Minute Anti-HB~ In First Layer _ _ ___ l/5 ~
1! 50 light BN
lt225 very light BN
1/625 no color (com~lete binding by reference an~i.gen~
1/3125 no color ~ 3 E~Eer ______(b).2 A l/625 dilution (from table (b)l above of conjugate was chosen for detection of HBA at l~0 nanograms/ml.
Test_ Sample Color Reaction 30 sec l min HBA present light BN BN
HBA absent no color no color The techni~ue of the present invention is equally appli-c~ble to both the detection of antibodies as well as antigens.
The roles of the antigen and antibody would be sim~ly reversed, For detecting antibodies, the antigen is labeled with enzyme and the reference antibody is immobiliæed in the first zone.
The enzyne labeled antigen will bind to the immobilized antibody in the first zone in the absence of competing antibody in the test sample, and fail to diffuse into the second zone to form a color. If antibodies are present in the test sample they will compete with the immobilized reference antibodies. In this case a ~ositive color reaction indicates the presence of antibodies in the test sample.
When the present invention is adapted to the detection of antibodies, a device is utilized which comprise~ a first zone containing enzyme-linked antigens and antibodies which are capable o~ immunologically reacting with said antigens, said antigens being positioned in said first zone such that they will be removed from said first zone when reacted with antibodies pass-ing into or through said irst zone but not removed from said first zone in the absence of such antibodies; and a second zone containing material capable of reacting, either directly or indir-ectly, with said enævme-linked antlgens to produce a color form-ing reaction which indicates the presence of said antigens.
While ~here have been described what are at present considered to be the preferred em~odiments of this invention, it will be obvious to those skilled in the art that various changes and modifications may be made therein without departing from the invention, and it is, ~herefore, aimed in the appendPd claims to cover all such changes and modifications as ~all within the true spirit and scope of the inventionO

Claims (19)

THE EMBODIMENTS OF THE INVENTION IN WHICH AN EXCLUSIVE
PROPERTY OR PRIVILEGE IS CLAIMED ARE DEFINED AS FOLLOWS:
1. A device for determining the presence of antigens which comprise:
a first zone containing antigens and enzyme-linked anti-bodies which are capable of immunologically reacting with said antigens, said antibodies being positioned in said first zone such that they will be removed from said first zone when reacted with antigens passing through said first zone but not removed from said first zone in the absence of such antigens; and a second zone containing material capable of reacting with said enzyme linked antibodies to produce a color forming reaction which indicates the presence of said antibodies.
2. The device of claim 1 wherein said first and second zones are in a juxtapositioned relationship.
3. The device of claim 1 wherein said first zone con-tains enzyme-linked antibodies which are combined with specific antigens.
4. The device of claim 1 wherein said first zone con-sists of at least two individual layers, with one or said layers containing enzyme-linked antibodies and another layer containing specific antigen immobilized in said layer.
5. The device of claim 1 wherein said first zone is fabricated from nitrocellulose.
6. The device of claim 1 wherein said first zone is fabricated from a porous polymer gel.
7. The device of claim 1 wherein said first zone is fabricated from particles containing immobilized antigen or antibody trapped in a fibrous matrix.
8. The device of claim 1 wherein said second zone is fabricated from nitrocellulose.
9. A method for determining the presence of antigens in a biological fluid which comprises:

bringing a fluid which is to be tested for the presence of antigens into contact with a device having a first zone con-taining antigens and enzyme-linked antibodies which are capable of immunologically reacting with said antigens, said antibodies being positioned in said first zone such that they will be removed from said first zone when reacted with antigens passing through said first zone but not removed from said first zone in the absence of such antigens, and a second zone containing material capable of reacting with said enzyme-linked antibodies to produce a color forming reaction which indicates the presence of said antibodies;
allowing said fluid to permeate said device; and, observing the presence or absence of any color change in said second zone to thereby determine the presence or absence of the tested for antigen in said fluid.
10. The method of claim 9 wherein said first and second zones are in a juxtapositioned relationship.
11. The method of claim 9 wherein said first zone con-tains enzyme-linked antibodies which are combined with specific antigens.
12. The method of claim 9 wherein said first zone con-sists of at least two individual layers, with one of said layers containing enzyme-linked antibodies and another layer containing specific antigen immobilized in said layer.
13. The method of claim 9 wherein said first zone is fabricated from nitrocellulose.
14. The method of claim 9 wherein said second zone is fabricated from nitrocellulose,
15. The method of claim 9 wherein the antigen in said device is human chorionic gonadatrophin.
16. The method of claim 9 wherein the antigen in said device is hepatitis antigen.
17. The method of claim 9 wherein the antigen in said device is a rubella virus protein.
18. A device for determining the presence of antibodies which comprises:
a first zone containing enzyme-linked antigens and anti-bodies which are capable of immunologically reacting with said antigens, said antigens being positioned in said first zone such that they will be removed from said first zone when reacted with antibodies passing through said first zone but not removed from said first zone in the absence of such antibodies; and a second zone containing material capable of reacting with said enzyme-linked antigens to produce a color forming reaction which indicates the presence of said antigens.
19. A method for determining the presence of antibodies in a biological fluid which comprises:
bringing a fluid which is to be tested for the presence of antibodies into contact with a device having a first zone con-taining enzyme-linked antigens and antibodies which are capable of immunologically reacting with said antigens, said antigens being positioned in said first zone such that they will be removed from said first zone when reacted with antibodies pass-ing through said first zone but not removed from said first zone in the absence of such antibodies, and a second zone containing material capable of reacting with said enzyme-linked antigens to produce a color forming reaction which indicates the presence of said antigens;
allowing said fluid to permeate said device; and, observing the presence or absence of any color change in said second zone to thereby determine the presence or absence of the tested for antibodies in said fluid.
CA000411489A 1981-10-13 1982-09-15 Device and method for determining the presence of antigens Expired CA1200483A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US310,801 1981-10-13
US06/310,801 US4446232A (en) 1981-10-13 1981-10-13 Enzyme immunoassay with two-zoned device having bound antigens

Publications (1)

Publication Number Publication Date
CA1200483A true CA1200483A (en) 1986-02-11

Family

ID=23204169

Family Applications (1)

Application Number Title Priority Date Filing Date
CA000411489A Expired CA1200483A (en) 1981-10-13 1982-09-15 Device and method for determining the presence of antigens

Country Status (14)

Country Link
US (1) US4446232A (en)
JP (2) JPS5876763A (en)
BE (1) BE894662A (en)
CA (1) CA1200483A (en)
DE (1) DE3237046A1 (en)
DK (1) DK159407C (en)
FR (1) FR2514511B1 (en)
GB (1) GB2111676B (en)
GR (1) GR76996B (en)
IE (1) IE53533B1 (en)
IT (1) IT1149089B (en)
LU (1) LU84402A1 (en)
NL (1) NL192138C (en)
SE (1) SE462606B (en)

Families Citing this family (211)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5622871A (en) * 1987-04-27 1997-04-22 Unilever Patent Holdings B.V. Capillary immunoassay and device therefor comprising mobilizable particulate labelled reagents
US4446232A (en) * 1981-10-13 1984-05-01 Liotta Lance A Enzyme immunoassay with two-zoned device having bound antigens
US4604348A (en) * 1981-11-19 1986-08-05 New York Blood Center, Inc. Composition for use in immunoassays
US5073484A (en) * 1982-03-09 1991-12-17 Bio-Metric Systems, Inc. Quantitative analysis apparatus and method
GB8305197D0 (en) * 1983-02-24 1983-03-30 Amersham Int Plc Assay methods
JPS59170768A (en) * 1983-03-17 1984-09-27 Fuji Photo Film Co Ltd Multilayered analyzing element for non-isotope assay and assay method using said element
US4549655A (en) * 1983-12-05 1985-10-29 E. I. Du Pont De Nemours And Company Container for a layered chemical analysis system
CA1261743A (en) * 1984-07-23 1989-09-26 Shai Inbar Biological diagnostic assay product, and process utilizing labeled fab fragments
US4617265A (en) * 1984-09-19 1986-10-14 Board Of Regents, University Of Texas System Colony blot assay for enterotoxigenic bacteria
US4826759A (en) * 1984-10-04 1989-05-02 Bio-Metric Systems, Inc. Field assay for ligands
DE3445816C1 (en) * 1984-12-15 1986-06-12 Behringwerke Ag, 3550 Marburg Flat diagnostic agent
US4764459A (en) * 1984-12-28 1988-08-16 The United States Of America As Represented By The Department Of Health And Human Services Enzyme-linked immunosorbent assay (ELISA) for determining anti-bodies against herpes simplex virus (HSV) types 1 and 2 in human sera
IT1200382B (en) * 1985-02-08 1989-01-18 Boehringer Biochemia Srl DETECTION AND / OR DOSAGE SYSTEM OF CLINICAL PARAMETERS BY IMMUNO ENZYMATIC ROUTE
US4740468A (en) * 1985-02-14 1988-04-26 Syntex (U.S.A.) Inc. Concentrating immunochemical test device and method
US4859583A (en) * 1985-02-25 1989-08-22 Amoco Corporation Chemiluminescent immunochemical technique for low molecular weight antigens
US5879881A (en) * 1985-04-04 1999-03-09 Hybritech, Incorporated Solid phase system for use in ligand-receptor assays
US4824784A (en) * 1985-04-08 1989-04-25 Hygeia Sciences, Incorporated Chromogenic solution for immunoassay
JPS62502495A (en) * 1985-04-10 1987-09-24 イムニコン・コ−ポレ−ション Direct homogeneity test
US4746631A (en) * 1985-05-09 1988-05-24 Ultra Diagnostics Corporation Immunoassay method, device, and test kit
US4803170A (en) * 1985-05-09 1989-02-07 Ultra Diagnostics Corporation Competitive immunoassay method, device and test kit
US4931385A (en) * 1985-06-24 1990-06-05 Hygeia Sciences, Incorporated Enzyme immunoassays and immunologic reagents
US4774177A (en) * 1985-07-15 1988-09-27 Vet-Test Partners Immunoassay method for detection of antibodies and antigens
US4806312A (en) * 1985-08-28 1989-02-21 Miles Inc. Multizone analytical element having detectable signal concentrating zone
US4806311A (en) * 1985-08-28 1989-02-21 Miles Inc. Multizone analytical element having labeled reagent concentration zone
TW203120B (en) * 1985-10-04 1993-04-01 Abbott Lab
US4868106A (en) * 1985-10-17 1989-09-19 Konishiroku Photo Industry Co., Ltd. Analytical element and method for determining a component in a test sample
GB8526741D0 (en) * 1985-10-30 1985-12-04 Boots Celltech Diagnostics Binding assay device
US5500350A (en) * 1985-10-30 1996-03-19 Celltech Limited Binding assay device
AU6839587A (en) * 1985-12-10 1987-06-30 Murex Corp. Particle-bound binding component immunoassay
US5236826A (en) * 1985-12-10 1993-08-17 Murex Corporation Immunoassay for the detection or quantitation of an analyte
US5501949A (en) * 1985-12-10 1996-03-26 Murex Diagnostics Corporation Particle bound binding component immunoassay
US4868108A (en) * 1985-12-12 1989-09-19 Hygeia Sciences, Incorporated Multiple-antibody detection of antigen
JPH0814582B2 (en) * 1986-02-20 1996-02-14 富士写真フイルム株式会社 Multilayer analytical element for immunoreactant quantification
JPH0750114B2 (en) * 1986-03-17 1995-05-31 富士写真フイルム株式会社 Analysis method using immunoassay instrument
US5190864A (en) * 1986-04-15 1993-03-02 Northeastern University Enzyme amplification by using free enzyme to release enzyme from an immobilized enzyme material
US4801726A (en) * 1986-04-15 1989-01-31 Northeastern University Repetitive hit-and-run immunoassay and stable support-analyte conjugates; applied to T-2 toxin
US4937188A (en) * 1986-04-15 1990-06-26 Northeastern University Enzyme activity amplification method for increasing assay sensitivity
US4837145A (en) * 1986-06-09 1989-06-06 Liotta Lance A Layered immunoassay using antibodies bound to transport particles to determine the presence of an antigen
CA1289872C (en) * 1986-06-18 1991-10-01 David L. Woodrum Reversible immobilization of assay reagents in a multizone test device
CA1289876C (en) * 1986-07-15 1991-10-01 Richard R. Anderson Solid phase system incorporating tetrazolium salts for use in ligand-receptor assays
US20010023075A1 (en) * 1992-04-03 2001-09-20 Siu-Yin Wong A immunodiagnositc device having a dessicant incorporated therein
US5763262A (en) * 1986-09-18 1998-06-09 Quidel Corporation Immunodiagnostic device
DE3640318A1 (en) * 1986-11-26 1988-06-09 Boehringer Mannheim Gmbh METHOD AND TEST CARRIER FOR DETERMINING AN ANALYT
US4822747A (en) * 1986-12-09 1989-04-18 Miles Inc. Polyacrylamide gel particles having hapten moieties bound thereto as immunoassay reagent
GB8629740D0 (en) * 1986-12-12 1987-01-21 Iq Bio Ltd Immunoassay
ES2004066A6 (en) * 1987-01-21 1988-12-01 Euro Fassel Aktiebolag A kit for qualitative and quantitative analysis of antigens, antibodies and/or microorganisms or other cells
AU592174B2 (en) * 1987-02-17 1990-01-04 Genesis Labs, Inc. Immunoassay test strip
AU590071B2 (en) * 1987-02-25 1989-10-26 Genesis Labs, Inc. Dry test strips having a red blood cell exclusion layer preventing interference by red blood cells in analyte detection visualization
AU586552B2 (en) * 1987-02-25 1989-07-13 Genesis Labs, Inc. Dry test strip for devices using oxygen demanding detection system
USRE38430E1 (en) * 1987-03-27 2004-02-17 Becton, Dickinson And Company Solid phase chromatographic immunoassay
CA1303983C (en) * 1987-03-27 1992-06-23 Robert W. Rosenstein Solid phase assay
US4857453A (en) * 1987-04-07 1989-08-15 Syntex (U.S.A.) Inc. Immunoassay device
US4956275A (en) * 1987-04-14 1990-09-11 Molecular Devices Corporation Migratory detection immunoassay
DE3856421T2 (en) 1987-04-27 2000-12-14 Unilever Nv Specific binding test procedures
US4855240A (en) * 1987-05-13 1989-08-08 Becton Dickinson And Company Solid phase assay employing capillary flow
US5238847A (en) * 1987-05-20 1993-08-24 Boehringer Mannheim Gmbh Test kit and process for the determination of an analyte in a pasty sample
DE3716891A1 (en) * 1987-05-20 1988-12-15 Boehringer Mannheim Gmbh TEST KIT FOR DETERMINING ANALYTIC IN THE CHAIR
US4883764A (en) * 1987-07-20 1989-11-28 Kloepfer Mary A Blood test strip
IT1223295B (en) * 1987-08-14 1990-09-19 Boehringer Biochemia Srl IMMUNODIAGNOSTIC DEVICE AND METHOD
FR2621393B1 (en) * 1987-10-05 1991-12-13 Toledano Jacques DEVICE FOR IMMUNOENZYMATIC DETECTION OF SUBSTANCES FROM A DROP OF BLOOD OR LIQUID FROM ANY BIOLOGICAL MEDIUM
DE3740471A1 (en) * 1987-11-28 1989-06-08 Boehringer Mannheim Gmbh TEST SUPPLIER FOR THE ANALYSIS OF A SAMPLING FLUID AND METHOD FOR THE PRODUCTION THEREOF
AU2828889A (en) * 1987-12-14 1989-07-19 Lance A. Liotta Layered immunoassay device containing fluid flow barrier
US4870007A (en) * 1987-12-18 1989-09-26 Eastman Kodak Company Immobilized biotinylated receptor in test device, kit and method for determining a ligand
DE3887491T2 (en) * 1987-12-21 1994-07-07 Abbott Lab Chromatographic binding assay devices and methods.
WO1989006791A1 (en) * 1988-01-21 1989-07-27 Boehringer Mannheim Corporation Apparatus for determining an analyte and method therefor
WO1989006792A1 (en) * 1988-01-21 1989-07-27 Boehringer Mannheim Corporation Method and apparatus for analyte determination
EP0432155A4 (en) * 1988-02-16 1991-08-21 Boehringer Mannheim Corporation Analytical element which avoids premature reaction
USH1664H (en) * 1988-03-09 1997-07-01 Fuji Photo Film Co., Ltd. Analytical element for immunoassay and method for its preparation
DE3814370A1 (en) * 1988-04-28 1989-11-09 Boehringer Mannheim Gmbh TEST PROVIDER FOR THE ANALYSIS OF A SAMPLING FLUID, METHOD FOR CARRYING OUT SUCH ANALYSIS AND METHOD OF PRODUCTION
FR2630827B1 (en) * 1988-04-28 1994-06-03 Oris Ind APPARATUS AND METHOD FOR QUICK QUALITATIVE AND QUANTITATIVE DETERMINATION OF THE PRESENCE OF A REACTIVE LIGAND IN A FLUID
US5013669A (en) * 1988-06-01 1991-05-07 Smithkline Diagnostics, Inc. Mass producible biologically active solid phase devices
US4981785A (en) * 1988-06-06 1991-01-01 Ventrex Laboratories, Inc. Apparatus and method for performing immunoassays
EP0345460B1 (en) * 1988-06-09 1995-09-06 Abbott Laboratories Method and device employing covalently immobilized colored dyes
US5094962A (en) * 1988-06-13 1992-03-10 Eastman Kodak Company Microporous article having a stabilized specific binding reagent, a method for its use and a diagnostic test kit
AU2684488A (en) * 1988-06-27 1990-01-04 Carter-Wallace, Inc. Test device and method for colored particle immunoassay
FR2634891B1 (en) * 1988-08-01 1994-05-06 Biotrol Laboratoires METHOD AND DEVICE FOR THE QUALITATIVE AND / OR QUANTITATIVE DETERMINATION OF A LIGAND IN A FLUID
US5030555A (en) * 1988-09-12 1991-07-09 University Of Florida Membrane-strip reagent serodiagnostic apparatus and method
US5102788A (en) * 1988-11-21 1992-04-07 Hygeia Sciences, Inc. Immunoassay including lyophilized reactant mixture
DE3842702A1 (en) * 1988-12-19 1990-06-21 Boehringer Mannheim Gmbh TEST CARRIER FOR ANALYTICAL EXAMINATION OF A SAMPLING LIQUID WITH THE AID OF A SPECIFIC BINDING REACTION OF TWO BIOAFFIN BINDING PARTNERS AND A CORRESPONDING TEST PROCEDURE
US5028535A (en) * 1989-01-10 1991-07-02 Biosite Diagnostics, Inc. Threshold ligand-receptor assay
US5939272A (en) * 1989-01-10 1999-08-17 Biosite Diagnostics Incorporated Non-competitive threshold ligand-receptor assays
US5200317A (en) * 1989-02-02 1993-04-06 Abbott Laboratories Method and device for quantitative chromatography
US5045480A (en) * 1989-02-09 1991-09-03 Miles Inc. Gel particles having hapten moieties bound thereto as immunoassay reagent
US6352862B1 (en) 1989-02-17 2002-03-05 Unilever Patent Holdings B.V. Analytical test device for imuno assays and methods of using same
US5766933A (en) * 1989-04-26 1998-06-16 Diagnostic Products Corporation Method and element for measuring analytes in biological fluids using immobilized binder--analyte labeled complex
DE3941150A1 (en) * 1989-12-13 1991-06-20 Boehringer Mannheim Gmbh METHOD FOR DETERMINING AN ANALYTE
US5252496A (en) * 1989-12-18 1993-10-12 Princeton Biomeditech Corporation Carbon black immunochemical label
EP0513209A4 (en) * 1990-01-26 1993-08-25 Us Commerce A method for quantitatively measuring collagenase
US5922615A (en) 1990-03-12 1999-07-13 Biosite Diagnostics Incorporated Assay devices comprising a porous capture membrane in fluid-withdrawing contact with a nonabsorbent capillary network
US5468622A (en) * 1990-04-03 1995-11-21 Immunomatrix, Inc. Salt stabilization of antibody-enzyme conjugates heat-dried into paper
DE4013004C2 (en) * 1990-04-24 1993-10-21 Elvira Schecklies Method for the quantitative determination of low molecular weight organic substances
US5212060A (en) * 1990-04-27 1993-05-18 Genesis Labs, Inc. Dry test strip comprising a dextran barrier for excluding erythrocytes
US5139934A (en) * 1990-05-25 1992-08-18 Becton, Dickinson And Company Substrate composition and method for solid phase urease immunoassay
DE69119312T2 (en) * 1990-07-18 1997-01-16 Abbott Lab Analyte exchange reagent for use in specific binding assays, devices and sets
US5166051A (en) * 1990-08-08 1992-11-24 Genesis Labs, Inc. Membranes, membrane overlays for exclusion of erythrocytes, and method for immunoassay of whole blood analytes
US5200321A (en) * 1990-09-07 1993-04-06 The United States Of America As Represented By The Secretary Of The Navy Microassay on a card
US5143852A (en) * 1990-09-14 1992-09-01 Biosite Diagnostics, Inc. Antibodies to ligand analogues and their utility in ligand-receptor assays
WO1992005282A1 (en) * 1990-09-14 1992-04-02 Biosite Diagnostics, Inc. Antibodies to complexes of ligand receptors and ligands and their utility in ligand-receptor assays
FR2667943B1 (en) * 1990-10-11 1994-05-13 Jacques Toledano DEVICE AND METHOD FOR THE QUICK QUALITATIVE AND QUANTITATIVE DETERMINATION OF A LIGAND IN A FLUID.
US5166054A (en) * 1991-01-02 1992-11-24 Becton, Dickinson And Company Method for immunoassay using lactoperoxidase, starch and iodine
CA2065719A1 (en) 1991-04-30 1992-10-31 John B. Findlay Nucleic acid amplification and detection methods using rapid polymerase chain reaction cycle
US6168956B1 (en) 1991-05-29 2001-01-02 Beckman Coulter, Inc. Multiple component chromatographic assay device
US5468648A (en) * 1991-05-29 1995-11-21 Smithkline Diagnostics, Inc. Interrupted-flow assay device
US5998220A (en) 1991-05-29 1999-12-07 Beckman Coulter, Inc. Opposable-element assay devices, kits, and methods employing them
US5607863A (en) * 1991-05-29 1997-03-04 Smithkline Diagnostics, Inc. Barrier-controlled assay device
US5869345A (en) * 1991-05-29 1999-02-09 Smithkline Diagnostics, Inc. Opposable-element assay device employing conductive barrier
US5877028A (en) 1991-05-29 1999-03-02 Smithkline Diagnostics, Inc. Immunochromatographic assay device
DE4121493A1 (en) * 1991-06-28 1993-01-07 Draegerwerk Ag ANALYSIS DEVICE FOR THE QUANTITATIVE, IMMUNOLOGICAL DETERMINATION OF POLLUTANTS
EP0525723B1 (en) * 1991-07-29 1997-05-14 Mochida Pharmaceutical Co., Ltd. Process and device for specific binding assay
WO1993021530A1 (en) * 1992-04-10 1993-10-28 Messerschmitt-Bölkow-Blohm Gmbh PROCESS AND DEVICE FOR INCREASING THE SENSITIVITY AND SELECTIVITY OF IMMUNO-ASSAYS, MOLECULE-RECEPTOR, DNA-COMPLEMENTARY DNA and FOREIGN MOLECULE-HOST MOLECULE INTERACTION ASSAYS
DE4217474A1 (en) * 1992-05-27 1993-12-02 Boehringer Mannheim Gmbh Method and means for determining an analyte
FR2702841B1 (en) * 1993-03-19 1996-01-26 Toledano Jacques Device and peptide-anti-peptide immunological method.
US5837546A (en) * 1993-08-24 1998-11-17 Metrika, Inc. Electronic assay device and method
FR2709349B1 (en) * 1993-08-25 1995-10-27 Stago Diagnostica Method of identifying an immunological substance by means of a multimembrane system.
US5512448A (en) * 1994-04-28 1996-04-30 Yamazaki; Hiroshi Stabilization of peroxidase conjugates in solution
US5589344A (en) 1994-06-15 1996-12-31 Johnson & Johnson Clinical Diagnostics, Inc. Test kit and method for competitive specific binding assay
US6653066B1 (en) 1994-06-17 2003-11-25 Trinity Biotech Device and method for detecting polyvalent substances
US6686170B1 (en) 1994-08-17 2004-02-03 Abbott Laboratories Assay devices with mobile control reagents
US5597532A (en) * 1994-10-20 1997-01-28 Connolly; James Apparatus for determining substances contained in a body fluid
US5780239A (en) * 1994-11-23 1998-07-14 Carter; Jesse M. Method for the determination of cast in urine
US5569608A (en) * 1995-01-30 1996-10-29 Bayer Corporation Quantitative detection of analytes on immunochromatographic strips
US5739041A (en) * 1995-05-02 1998-04-14 Carter Wallace, Inc. Diagnostic detection device
US20010051350A1 (en) * 1995-05-02 2001-12-13 Albert Nazareth Diagnostic detection device and method
WO1997001759A1 (en) * 1995-06-28 1997-01-16 Popbb Snc Improved immunological test device
US5741714A (en) * 1995-07-18 1998-04-21 Immunivest Corporation Detection of bound analyte by magnetic partitioning and masking
US7635597B2 (en) 1995-08-09 2009-12-22 Bayer Healthcare Llc Dry reagent particle assay and device having multiple test zones and method therefor
US5660990A (en) * 1995-08-18 1997-08-26 Immunivest Corporation Surface immobilization of magnetically collected materials
DE19540541A1 (en) * 1995-10-31 1997-05-07 Human Ges Fuer Biochemica Und Test device and test procedure
DK0799894T3 (en) * 1996-02-09 2004-08-09 Degussa Process for the preparation of (S) -cyanhydrins
US5968839A (en) * 1996-05-13 1999-10-19 Metrika, Inc. Method and device producing a predetermined distribution of detectable change in assays
US5942407A (en) * 1996-06-25 1999-08-24 Immunomatrix, Inc. Light-emitting immunoassay
US5945345A (en) * 1996-08-27 1999-08-31 Metrika, Inc. Device for preventing assay interference using silver or lead to remove the interferant
US6001658A (en) * 1996-09-13 1999-12-14 Diagnostic Chemicals Limited Test strip apparatus and method for determining presence of analyte in a fluid sample
US5879951A (en) * 1997-01-29 1999-03-09 Smithkline Diagnostics, Inc. Opposable-element assay device employing unidirectional flow
US20050101032A1 (en) * 1997-02-10 2005-05-12 Metrika, Inc. Assay device, composition, and method of optimizing assay sensitivity
US5939252A (en) * 1997-05-09 1999-08-17 Lennon; Donald J. Detachable-element assay device
US5895765A (en) * 1997-06-30 1999-04-20 Bayer Corporation Method for the detection of an analyte by immunochromatography
US6436721B1 (en) 1997-07-25 2002-08-20 Bayer Corporation Device and method for obtaining clinically significant analyte ratios
US6824985B1 (en) * 1997-09-09 2004-11-30 Bayer Corporation Formulation for reducing urea effect for immunochromatography assays using urine samples
US5972595A (en) * 1997-12-19 1999-10-26 Nen Life Science Products, Inc. Enzyme assay using a solid phase substrate
US6066446A (en) * 1997-12-19 2000-05-23 Nen Life Science Products, Inc. Assay member and method for its manufacture
US6303081B1 (en) 1998-03-30 2001-10-16 Orasure Technologies, Inc. Device for collection and assay of oral fluids
US8062908B2 (en) * 1999-03-29 2011-11-22 Orasure Technologies, Inc. Device for collection and assay of oral fluids
DK1696236T3 (en) * 1998-03-30 2014-08-18 Orasure Technologies Inc Collection device for analysis of oral fluids
US20060019404A1 (en) * 1998-05-06 2006-01-26 Blatt Joel M Quantitative assay with extended dynamic range
US7799521B2 (en) * 1998-06-24 2010-09-21 Chen & Chen, Llc Thermal cycling
US6780617B2 (en) 2000-12-29 2004-08-24 Chen & Chen, Llc Sample processing device and method
JP3395673B2 (en) 1998-11-18 2003-04-14 株式会社豊田中央研究所 Specific binding pair measurement method using micro oxygen electrode
US6171295B1 (en) * 1999-01-20 2001-01-09 Scimed Life Systems, Inc. Intravascular catheter with composite reinforcement
US7577469B1 (en) 1999-03-11 2009-08-18 Jack L. Aronowitz Noninvasive transdermal systems for detecting an analyte in a biological fluid and methods
DE10003734A1 (en) * 2000-01-28 2001-08-02 Bosch Gmbh Robert Detection method and device
US6998273B1 (en) 2000-02-09 2006-02-14 A-Fem Medical Corporation Collection device for lateral flow chromatography
US6365417B1 (en) 2000-02-09 2002-04-02 A-Fem Medical Corporation Collection device for lateral flow chromatography
US20020132370A1 (en) * 2000-02-23 2002-09-19 Lassen Michael Rud Detection of a blood coagulation activity marker in a body fluid sample
US6699722B2 (en) 2000-04-14 2004-03-02 A-Fem Medical Corporation Positive detection lateral-flow apparatus and method for small and large analytes
RU2278612C2 (en) * 2000-07-14 2006-06-27 Лайфскен, Инк. Immune sensor
US8124348B2 (en) * 2000-08-23 2012-02-28 Jonathan Zmuda Oral fluid rapid assay for hepatitis C virus (HCV) antibodies using non-antibody labeling of IgA molecules recognizing HCV peptide epitopes
US6584781B2 (en) 2000-09-05 2003-07-01 Enersea Transport, Llc Methods and apparatus for compressed gas
US7087389B2 (en) * 2001-02-09 2006-08-08 Council Of Scientific & Industrial Research Highly cost-effective analytical device for performing immunoassays with ultra high sensitivity
DE10108680A1 (en) * 2001-02-23 2002-09-26 Biognostic Ag Test strips for the assay of biological materials, for clinical diagnosis etc. carry affinity molecules and can take or support a flow to give time-related reactions
US20050266499A1 (en) * 2001-04-25 2005-12-01 Rockeby Biomed Corporation, Ltd. Method and apparatus for testing for presence or absence of select biological substances
AT5044U1 (en) * 2001-05-10 2002-02-25 Medsystems Diagnostics Gmbh QUANTITATIVE ONE-STEP IMMUNITY TEST IN LYOPHILIZED FORM
US7531362B2 (en) * 2001-06-07 2009-05-12 Medmira Inc. Rapid diagnostic assay
US7270959B2 (en) 2001-07-25 2007-09-18 Oakville Hong Kong Company Limited Specimen collection container
US7300633B2 (en) 2001-07-25 2007-11-27 Oakville Hong Kong Company Limited Specimen collection container
JP4513085B2 (en) * 2001-09-11 2010-07-28 アイキューム インク Sample container
US20030124618A1 (en) * 2001-12-04 2003-07-03 Lattec I/S Device for analysing analyte compounds and use hereof
US7459127B2 (en) * 2002-02-26 2008-12-02 Siemens Healthcare Diagnostics Inc. Method and apparatus for precise transfer and manipulation of fluids by centrifugal and/or capillary forces
US20030180814A1 (en) * 2002-03-21 2003-09-25 Alastair Hodges Direct immunosensor assay
US20060134713A1 (en) * 2002-03-21 2006-06-22 Lifescan, Inc. Biosensor apparatus and methods of use
JP3637392B2 (en) * 2002-04-08 2005-04-13 独立行政法人産業技術総合研究所 Fuel cell
US20030232401A1 (en) * 2002-06-12 2003-12-18 Pugia Michael J. Bacterial test method by glycated label binding
US7108993B2 (en) * 2002-07-19 2006-09-19 Bayer Healthcare Llc Use of dual conjugated labels in the elimination of serum interference in immunochromatographic assays
US20040038197A1 (en) * 2002-08-22 2004-02-26 Usda Ars Ott Extraction and concentration method
US20040092036A1 (en) * 2002-09-11 2004-05-13 Lattec I/S Device for analysing analyte compounds and use hereof
US7093166B2 (en) * 2002-10-08 2006-08-15 Dell Products L.P. Method and apparatus for testing physical memory in an information handling system under conventional operating systems
US7094354B2 (en) * 2002-12-19 2006-08-22 Bayer Healthcare Llc Method and apparatus for separation of particles in a microfluidic device
US7125711B2 (en) * 2002-12-19 2006-10-24 Bayer Healthcare Llc Method and apparatus for splitting of specimens into multiple channels of a microfluidic device
JP4667874B2 (en) * 2002-12-26 2011-04-13 メソ スケール テクノロジーズ エルエルシー Methods, compositions and kits for extracting biomarkers
US7560272B2 (en) 2003-01-04 2009-07-14 Inverness Medical Switzerland Gmbh Specimen collection and assay container
WO2004080597A2 (en) 2003-02-05 2004-09-23 Iquum, Inc. Sample processing tubule
US8101429B2 (en) * 2003-06-03 2012-01-24 Siemens Healthcare Diagnostics Inc. Native analyte as a reference in lateral flow assays
US20080257754A1 (en) * 2003-06-27 2008-10-23 Pugia Michael J Method and apparatus for entry of specimens into a microfluidic device
US20040265171A1 (en) * 2003-06-27 2004-12-30 Pugia Michael J. Method for uniform application of fluid into a reactive reagent area
US20040265172A1 (en) * 2003-06-27 2004-12-30 Pugia Michael J. Method and apparatus for entry and storage of specimens into a microfluidic device
US7347617B2 (en) * 2003-08-19 2008-03-25 Siemens Healthcare Diagnostics Inc. Mixing in microfluidic devices
US7517495B2 (en) 2003-08-25 2009-04-14 Inverness Medical Switzerland Gmbh Biological specimen collection and analysis system
US7943395B2 (en) * 2003-11-21 2011-05-17 Kimberly-Clark Worldwide, Inc. Extension of the dynamic detection range of assay devices
US7150995B2 (en) * 2004-01-16 2006-12-19 Metrika, Inc. Methods and systems for point of care bodily fluid analysis
US20050227370A1 (en) * 2004-03-08 2005-10-13 Ramel Urs A Body fluid analyte meter & cartridge system for performing combined general chemical and specific binding assays
US7319032B2 (en) * 2004-04-22 2008-01-15 Medtox Non-sugar sweeteners for use in test devices
DE102006058374A1 (en) * 2006-12-08 2008-07-03 Biosensor Gmbh Analytical method and portable analyzer
US20110118141A1 (en) * 2008-07-22 2011-05-19 Siemens Healthcare Diagnostics Inc. Disease Specific Diagnostic Aid
US8012770B2 (en) 2009-07-31 2011-09-06 Invisible Sentinel, Inc. Device for detection of antigens and uses thereof
US9475049B2 (en) 2009-07-31 2016-10-25 Invisible Sentinel, Inc. Analyte detection devices, multiplex and tabletop devices for detection of analyte, and uses thereof
CA2777061C (en) 2009-10-09 2018-06-19 Invisible Sentinel, Inc. Device for detection of analytes and uses thereof
EP2506012A4 (en) * 2009-11-24 2014-01-15 Korea Res Inst Of Bioscience Membrane biosensor to which a porous film is attached, and a method for measuring immune reactions or enzyme reactions employing the same
US8956859B1 (en) 2010-08-13 2015-02-17 Aviex Technologies Llc Compositions and methods for determining successful immunization by one or more vaccines
US20140322724A1 (en) * 2011-12-13 2014-10-30 Kieran Walshe Homogeneous competitive lateral flow assay
US8293487B1 (en) * 2012-01-06 2012-10-23 Jiandi Zhang Zestern, a simple, fast, specific and quantifiable improvement of immunodetection process
NZ629703A (en) 2012-03-09 2016-05-27 Invisible Sentinel Inc Methods and compositions for detecting multiple analytes with a single signal
US20130280696A1 (en) 2012-04-23 2013-10-24 Elliott Millenson Devices and methods for detecting analyte in bodily fluid
WO2014025415A2 (en) 2012-08-08 2014-02-13 Scanadu Incorporated Method and apparatus for performing and quantifying color changes induced by specific concentrations of biological analytes in an automatically calibrated environment
US9528941B2 (en) 2012-08-08 2016-12-27 Scanadu Incorporated Method and apparatus for determining analyte concentration by quantifying and interpreting color information captured in a continuous or periodic manner
US9285323B2 (en) 2012-08-08 2016-03-15 Scanadu Incorporated Quantifying color changes of chemical test pads induced concentrations of biological analytes under different lighting conditions
CN106232832B (en) * 2013-12-06 2022-04-05 哈佛大学校长及研究员协会 Synthetic gene networks based on paper
US9863811B2 (en) 2014-08-15 2018-01-09 Scanadu Incorporated Precision luxmeter methods for digital cameras to quantify colors in uncontrolled lighting environments
US9927443B2 (en) 2015-04-10 2018-03-27 Conquerab Inc. Risk assessment for therapeutic drugs
AU2016349703A1 (en) 2015-11-06 2018-11-01 Vetica Labs, Inc. Methods of detecting inflammatory markers and treating inflammatory conditions in companion animals
US9903866B2 (en) 2016-04-05 2018-02-27 Conquerab Inc. Portable devices for detection of antibodies against therapeutic drugs
WO2020241871A1 (en) * 2019-05-30 2020-12-03 国立大学法人北海道大学 Substance detecting device

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3654090A (en) * 1968-09-24 1972-04-04 Organon Method for the determination of antigens and antibodies
NL154600B (en) * 1971-02-10 1977-09-15 Organon Nv METHOD FOR THE DETERMINATION AND DETERMINATION OF SPECIFIC BINDING PROTEINS AND THEIR CORRESPONDING BINDABLE SUBSTANCES.
US3723064A (en) * 1971-07-26 1973-03-27 L Liotta Method and device for determining the concentration of a material in a liquid
FI49086C (en) * 1973-01-25 1975-03-10 Matti Antero Reunanen Radioimmunoassay.
US3926732A (en) * 1973-02-16 1975-12-16 Alfa Laval Ab Method for assaying catalase in milk and other liquids
US3992158A (en) * 1973-08-16 1976-11-16 Eastman Kodak Company Integral analytical element
US4039652A (en) * 1973-10-11 1977-08-02 Miles Laboratories, Inc. Column method of immunoassay employing an immobilized binding partner
SE388694B (en) * 1975-01-27 1976-10-11 Kabi Ab WAY TO PROVIDE AN ANTIGEN EXV IN SAMPLES OF BODY WHEATS, USING POROST BERAR MATERIAL BONDED OR ADSORBING ANTIBODIES
CA1054034A (en) * 1975-06-20 1979-05-08 Barbara J. Bruschi Multilayer analytical element
US4042335A (en) * 1975-07-23 1977-08-16 Eastman Kodak Company Integral element for analysis of liquids
US4016043A (en) * 1975-09-04 1977-04-05 Akzona Incorporated Enzymatic immunological method for the determination of antigens and antibodies
US4059407A (en) * 1976-04-14 1977-11-22 Becton, Dickinson And Company Disposable chemical indicators
US4094647A (en) * 1976-07-02 1978-06-13 Thyroid Diagnostics, Inc. Test device
JPS5344622A (en) * 1976-09-30 1978-04-21 Mochida Pharm Co Ltd Immunologically measuring method
US4200690A (en) * 1976-12-16 1980-04-29 Millipore Corporation Immunoassay with membrane immobilized antibody
CA1095819A (en) * 1977-01-14 1981-02-17 Eastman Kodak Company Element for analysis of liquids
US4277560A (en) * 1978-10-24 1981-07-07 Technicon Instruments Corporation Enzyme immunoassays using immobilized reagents in a flowing stream
JPH0142041Y2 (en) * 1978-12-11 1989-12-11
US4258001A (en) * 1978-12-27 1981-03-24 Eastman Kodak Company Element, structure and method for the analysis or transport of liquids
US4181501A (en) * 1979-03-26 1980-01-01 General Electric Company Method and apparatus for measuring antibody levels
US4264560A (en) * 1979-12-26 1981-04-28 Samuel Natelson Clinical analytical system
JPS5767860A (en) * 1980-10-15 1982-04-24 Fuji Photo Film Co Ltd Material for multilayer analysis
US4446232A (en) * 1981-10-13 1984-05-01 Liotta Lance A Enzyme immunoassay with two-zoned device having bound antigens

Also Published As

Publication number Publication date
FR2514511B1 (en) 1986-02-21
DE3237046C2 (en) 1988-08-04
BE894662A (en) 1983-04-11
GR76996B (en) 1984-09-04
DK159407C (en) 1991-04-02
SE8205751D0 (en) 1982-10-08
US4446232A (en) 1984-05-01
GB2111676A (en) 1983-07-06
NL192138C (en) 1997-02-04
LU84402A1 (en) 1983-06-13
DK451982A (en) 1983-04-14
NL192138B (en) 1996-10-01
IE53533B1 (en) 1988-12-07
NL8203946A (en) 1983-05-02
GB2111676B (en) 1985-08-21
SE462606B (en) 1990-07-23
DK159407B (en) 1990-10-08
SE8205751L (en) 1983-04-14
DE3237046A1 (en) 1983-04-21
IT8249171A0 (en) 1982-09-27
IT1149089B (en) 1986-12-03
FR2514511A1 (en) 1983-04-15
JPH0464062A (en) 1992-02-28
JPH0416745B2 (en) 1992-03-25
JPS5876763A (en) 1983-05-09
IE822464L (en) 1983-04-13

Similar Documents

Publication Publication Date Title
CA1200483A (en) Device and method for determining the presence of antigens
US5958790A (en) Solid phase transverse diffusion assay
EP0462376B1 (en) Conjugate recovery binding assays
JP2609438B2 (en) Test method
US7241628B2 (en) Method for immobilizing conjugates in diagnostic tests
US5081013A (en) Immunodiagnostic device and method
CA1289875C (en) Immunoassay test strip
JPH06317595A (en) Complementary visual sense signal immunoassay
AU592971B2 (en) Solid phase diffusion assay
AU601993B2 (en) Process and agent for the detection of an analyte
US5093081A (en) Dry-type analytical element for immunoassay
US20020006633A1 (en) Assay for anti transglutaminase antibodies detection useful in celicac disease diagnosis
EP0902287B1 (en) Method and test strip for reducing urea effect of immunochromatographic assays using urine samples
EP0643836B1 (en) Agglutination assays and kits employing colloidal dyes
JPS63210664A (en) Dry test piece for device using oxygen demand detection system and detecting method of analytic component in fluid to be inspected
US5603898A (en) Dry-type analytical element for immunoassay
JP2002214236A (en) Method and device for detecting antigen in blood
JP2616806B2 (en) Dry immunoassay element
JPH0382962A (en) Method of detecting antibody to hepatitis b virus core antigen
JPH026753A (en) Enzyme immune analysis
JPH0814580B2 (en) Dry immunoassay element
Grenner Principles and Applications of Heterogeneous Enzyme Immunoassays
Monroe Enzyme Channelling Immunoassay (ECIA): A Unique and Rapid Quantitative Technique

Legal Events

Date Code Title Description
MKEX Expiry